ArticleJournal of translational medicine2026
Vδ1 T cells exhibit high lactic acid resistance and antitumor activity in solid tumors.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundVδ1 T cells are promising for solid tumor immunotherapy but limited by peripheral rarity and inefficient expansion. This study aimed to establish a scalable expansion protocol and evaluate the therapeutic potential of unmodified and CAR-engineered Vδ1 T cells.
methodVδ1 T cells were expanded with a patented humanized Vδ1 TCR antibody plus cytokine cocktail (vs. commercial protocols). Transcriptomic profiling, in vitro cytotoxicity assays, in vivo xenograft experiments (vs. Vδ2 T cells), and PARP1-mediated lactate resistance analyses were performed. MSLN/NCL-targeted CAR-Vδ1 T cells were constructed and validated in OVCAR8-baring mice models.
resultsAverage 1 × 10¹⁰ high-purity Vδ1 T cells were obtained from 10 mL peripheral blood, outperforming commercial protocols. Expanded cells retained a stem-like phenotype, exerted superior antitumor activity vs. Vδ2 T cells, and resisted lactate-induced apoptosis via high PARP1 expression. CAR and IL-15 modified Vδ1 T cells showed potent anti-tumor efficacy.
conclusionsThis efficient Vδ1 T cell expansion protocol overcomes key clinical translation barriers. Vδ1 and CAR-Vδ1 T cells represent a novel off-the-shelf immunotherapeutic strategy for solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.